La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Livzon Pharmaceutical Group Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Livzon Pharmaceutical Group ha un patrimonio netto totale di CN¥15.4B e un debito totale di CN¥3.6B, che porta il suo rapporto debito/patrimonio netto a 23%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥25.2B e CN¥9.8B. L'EBIT di Livzon Pharmaceutical Group è CN¥2.0B rendendo il suo rapporto di copertura degli interessi -5.7. Ha liquidità e investimenti a breve termine pari a CN¥11.2B.

Informazioni chiave

23.0%

Rapporto debito/patrimonio netto

CN¥3.56b

Debito

Indice di copertura degli interessi	-5.7x
Contanti	CN¥11.23b
Patrimonio netto	CN¥15.44b
Totale passività	CN¥9.75b
Totale attività	CN¥25.19b

Aggiornamenti recenti sulla salute finanziaria

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Recent updates

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Aug 09

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Jul 02

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥17.2B ) di 000513 superano le sue passività a breve termine ( CN¥8.3B ).

Passività a lungo termine: Le attività a breve termine di 000513 ( CN¥17.2B ) superano le sue passività a lungo termine ( CN¥1.4B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 000513 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 000513 è aumentato da 0.01% a 23% negli ultimi 5 anni.

Copertura del debito: Il debito di 000513 è ben coperto dal flusso di cassa operativo ( 108.9% ).

Copertura degli interessi: 000513 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Livzon Pharmaceutical Group Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Recent updates

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Now 21% undervalued after recent price drop

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥1.35

Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2020 Results on Oct 23, 2020

Price target raised to CN¥51.22

Earnings released

Livzon Pharmaceutical Group Inc. to Report First Half, 2020 Results on Aug 26, 2020

New 90-day high - CN¥56.12

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane